Affinity maturation and functional dissection of a humanised anti-rage monoclonal antibody by ribosome display

Methods in Molecular Biology

Volumn 805, Issue , 2012, Pages 403-422

  Hufton, Simon E ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Affinity maturation; Antibody humanization; Mutational scanning; Ribosome display

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; DIRECTED MOLECULAR EVOLUTION; GENETICS; HUMAN; IMMUNOLOGY; POLYMERASE CHAIN REACTION; RIBOSOME;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; DIRECTED MOLECULAR EVOLUTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; POLYMERASE CHAIN REACTION; RIBOSOMES;

EID: 84555196322     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-379-0_23     Document Type: Article

References (15)

1. Carter, P. J. (2006) Potent antibody therapeutics by design, Nat. Rev. Immunol. 6, 343-357.
2. Schier R, McCall A, Adams GP et al (1996) Isolation of picomolar affi nity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site, J. Mol. Biol. 263, 551-567. (Pubitemid 26382075)
3. Schier R, Bye J, Apell G et al (1996) Isolation of high-affi nity monomeric human anti-cerbB-2 single chain Fv using affi nity-driven selection, J. Mol. Biol. 255, 28-43. (Pubitemid 26104182)
4. Thom G, Cockroft AC, Buchanan AG et al (2006) Probing a protein-protein interaction by in vitro evolution, Proc. Natl. Acad. Sci. U. S. A 103, 7619-7624.
5. Luginbuhl B, Kanyo Z, Jones RM et al (2006) Directed evolution of an anti-prion protein scFv fragment to an affi nity of 1 pM and its structural interpretation, J. Mol. Biol. 363, 75-97. (Pubitemid 44414837)
6. Graff CP, Chester K, Begent R et al (2004) Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C, Protein Eng Des Sel 17, 293-304. (Pubitemid 39093509)
7. Wu H, Beuerlein G, Nie Y et al (1998) Stepwise in vitro affi nity maturation of Vitaxin, an alpha v beta3-specifi c humanized mAb, Proc. Natl. Acad. Sci. U. S. A 95, 6037-6042.
8. Wu H, Pfarr DS, Tang Y et al (2005) Ultrapotent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization, J. Mol. Biol. 350, 126-144. (Pubitemid 40804737)
9. Wu H, Pfarr DS, Johnson S et al (2007) Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract, J. Mol. Biol. 368, 652-665. (Pubitemid 46527610)
10. Lu D, Shen J, Vil MD et al (2003) Tailoring in vitro selection for a picomolar affi nity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity, J. Biol. Chem. 278, 43496-43507. (Pubitemid 37345973)
11. Finlay WJ, Cunningham O, Lambert MA et al (2009) Affi nity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions, J. Mol. Biol. 388, 541-558.
12. Barbas CF III, Bain JD, Hoekstra DM et al (1992) Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem, Proc. Natl. Acad. Sci. U. S. A 89, 4457-4461.
13. Jermutus L, Honegger A, Schwesinger F et al (2001) Tailoring in vitro evolution for protein affi nity or stability, Proc. Natl. Acad. Sci. U. S. A 98, 75-80. (Pubitemid 32095866)
14. Lutterloh EC, Opal SM, Pittman, DD et al (2007) Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection, Crit Care 11, R122.
15. Hanes J, Jermutus L, Pluckthun A. (2000) Selecting and evolving functional proteins in vitro by ribosome display, Methods Enzymol. 328, 404-430.